Lenalidomide for refractory cutaneous manifestations of paediatric systemic lupus erythematosus

OBJECTIVE: Cutaneous manifestations of paediatric systemic lupus erythematosus (pSLE) cause significant morbidity. Lenalidomide, a thalidomide analogue, has shown promise treating cutaneous LE (CLE) in adults. Our objective was to evaluate lenalidomide's efficacy and safety in treating refracto...

Full description

Saved in:
Bibliographic Details
Published in:Lupus
Main Authors: Wu, Eveline Y., Schanberg, Laura E., Wershba, Elisa C., Rabinovich, C. Egla
Format: Artigo
Language:Inglês
Published: 2016
Subjects:
Article
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC5388573/
https://ncbi.nlm.nih.gov/pubmed/27837194
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/0961203316676377
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items